SCHEMBL240743

SCHEMBL240743

CCOC(=O)c1ccc(OC2CCC(N3C(=O)c4ccccc4C3=O)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
MAPK1 P28482 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.58
EPHX2 P34913 4/20 0.49
TSHR P16473 2/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.45
P2RX3 P56373 3/20 0.44
LMNA P02545 1/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12475054 1.00 ALDH1A1 (0.60) ALDH1A1MAPK1L3MBTL1EPHX2TSHR
SCHEMBL18809479 0.84 L3MBTL1 (0.52) ALDH1A1MAPK1L3MBTL1EPHX2TSHR
SCHEMBL11756971 0.82 LMNA (0.61) L3MBTL1EPHX2MAPTLMNA
SCHEMBL382607 0.81 L3MBTL1 (0.65) ALDH1A1MAPK1L3MBTL1TSHRMEN1
SCHEMBL12931837 0.79 EPHX2 (0.49) ALDH1A1L3MBTL1EPHX2TSHRKMT2A
SCHEMBL11758763 0.78 PARP10 (0.59) EPHX2MEN1KMT2AMAPTLMNA
SCHEMBL1063449 0.77 KMT2A (0.54) ALDH1A1L3MBTL1EPHX2TSHRMEN1
SCHEMBL1060542 0.77 KMT2A (0.54) ALDH1A1L3MBTL1EPHX2TSHRMEN1
SCHEMBL16997532 0.77 KMT2A (0.54) ALDH1A1L3MBTL1EPHX2TSHRMEN1
SCHEMBL1060544 0.77 KMT2A (0.54) ALDH1A1L3MBTL1EPHX2TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2675274-B1 SORAFENIB DERIVATIVES AS sEH INHIBITORS UNIV CALIFORNIA (US) 2017-05-03 EP disclosed
US-9029401-B2 Sorafenib derivatives as sEH inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-05-12 US disclosed
US-20140088156-A1 SORAFENIB DERIVATIVES AS SEH INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-03-27 US disclosed
EP-2675274-A1 SORAFENIB DERIVATIVES AS sEH INHIBITORS The Regents of the University of California (US) 2013-12-25 EP disclosed
WO-2012112570-A1 SORAFENIB DERIVATIVES AS sEH INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-23 WO disclosed
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2012-01-05 US disclosed
US-8053447-B2 11β-hydroxysteroid dehydrogenase type 1 active compounds HIGH POINT PHARMACEUTICALS, LLC (US) 2011-11-08 US disclosed
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004209-A1 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds HSD11B1, HSD3B1, HSD11B2 ALDH1A1 77/4885MAPK1 1300/4885L3MBTL1 4101/4885
US-20140088156-A1 SORAFENIB DERIVATIVES AS SEH INHIBITORS EPHX1, FAH, EPHX2 ALDH1A1 212/4885MAPK1 1240/4885L3MBTL1 3894/4885
US-20100292215-A1 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS HSD11B1, HSD3B1, HSD17B1 ALDH1A1 67/4885MAPK1 1304/4885L3MBTL1 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.